Inspiratory Pulmonary Rehabilitation for Children With Obesity and Asthma

Pediatric Obesity Clinical Trial

— iPro  

Official title:

Inspiratory Pulmonary Rehabilitation for Children With Obesity and Asthma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05608668
• Other study ID #: Pro00111393
• Status: Recruiting
• Phase: N/A
• Start date: July 27, 2023
• Est. completion date: June 2024

Study information

• Verified date: March 2023
• Source: Duke University
• Contact: Veronica Carrion, BS
• Phone: 9197041523
• Email: vmp19[@]duke.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single-center, randomized, SHAM-controlled, parallel assignment, double-masked,8-week interventional study among children aged 8-17 years (not yet 18 years old) of age with obesity and asthma. (n=60), recruited from Duke Health Center Creekstone, to test the effectiveness of inspiratory muscle rehabilitation (IMR) as an acceptable add-on intervention to reduce dyspnea (feeling short-of-breath or breathless) and to promote greater activity in children with obesity and asthma.

Clinic to test the effectiveness of inspiratory muscle rehabilitation (IMR) as an acceptable add-on intervention to reduce dyspnea (feeling short-of-breath or breathless) and to promote greater activity in children with obesity

Description:

Asthma is a chronic respiratory disease affecting roughly 8% of US children, and is characterized by intermittent symptoms of breathlessness/dyspnea, chest tightness, wheeze, and cough. Although asthma is currently the most common chronic disease in childhood, there are no cures and the underlying etiologies of the various asthma phenotypes still remain unclear. More than half of the 7-8 million pediatric asthma patients in the US have one or more exacerbations each year. A sizable component of asthma's impact on children stems from the recurrent mild-moderate symptoms that cause impaired quality-of-life, activity limitation and exercise avoidance. Uncontrolled asthma frequently disrupts quality of life and is the #1 reason that children miss school and avoid physical activity. Among children with asthma, obesity is a major risk factor for disruptive asthma symptoms. Asthma is conventionally thought to stem from inflammation in the lower airways. However, despite the widespread availability of anti-inflammatory inhaled corticosteroid (ICS) drugs, uncontrolled asthma remains extremely common and appears to be less effective in obese patients.

Pediatric obesity is a risk factor for both new-onset asthma and asthma that has more frequent and refractory symptoms. We found that pediatric obesity increases the risk for spirometry-confirmed asthma by nearly 30%. The mechanistic link between obesity and uncontrolled asthma remains unknown. In general, asthmatic children who are obese experience a reduced response to daily preventative ICS. Pediatric obesity has repeatedly been associated with more frequent and severe asthma symptoms, greater airflow obstruction, need for more frequent albuterol use, and more frequent and severe exacerbations. A consistent finding across most studies of children with both obesity and asthma has been an obesity-related increase in the frequency of chronic asthma symptoms (specifically dyspnea) and asthma-related activity limitation. We found that the greater asthma symptoms seen in obese versus non-obese children were primarily attributable to excess symptoms of dyspnea. Obese adolescents with asthma most commonly report that dyspnea is their most problematic asthma symptom. We hypothesize that the increased asthma symptom reporting in obese asthma, stems not from airway inflammation but rather obesity-related impaired breathing mechanics (i.e. chest restriction). Because of the reduced response to conventional asthma drugs and the resulting excess symptoms, there is a critical need for new treatment approaches for obese children with asthma that is guided by improved mechanistic understanding of this difficult phenotype.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: June 2024
• Est. primary completion date: June 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 8 Years to 17 Years

Eligibility

Inclusion Criteria:

• Documented informed consent from legal guardian and assent from participant as appropriate.

• Children 8 to 17 years of age with obesity (BMI = 95th percentile for age and sex) and mild asthma.

• Participants (or parent/guardian) must have access to the internet and an approved smart device/computer.

• Child must have a designated caregiver who expresses a commitment to encourage the participant to complete the study procedures.

• Participant and legal guardian must speak and read English.

• Child is currently taking prescription medicine for asthma (Any type of albuterol or inhaled steroid)

Exclusion Criteria:

• Prior intubation for asthma

• Current self-reported pregnancy or planning to become pregnant.

• Have an FEV1 < 50% of predicted at screening

• History of lung surgery in the past two years,

• History of pulmonary embolism in the past two years,

• Any history of recurrent spontaneous pneumothorax, or pneumothorax in the past 12 months

• Current undiagnosed chest pain,

• History of inner ear surgery in the past 12 months,

• Undiagnosed syncopal episodes in the past two years,

• Progressive neurological or neuromuscular disorders or need for chronic O2 therapy.

• Inability to complete baseline measurements satisfactorily according to the research coordinator's or PI's judgment.

• Any condition in the opinion of the PI that would not allow safe conduct of study procedures (including IMR, MIP testing or step-test), such as a physical disability, recent musculoskeletal injury or illness, current and ongoing evaluation for undiagnosed cardiopulmonary or neurologic symptoms

Related Conditions & MeSH terms

• Asthma
• Obesity
• Pediatric Asthma
• Pediatric Obesity

Intervention

Device:
• Pro2 - 60% of participant's MIP
Each participant will be provided a PrO2™ device and trained on its use as well as its accompanying PrO2 Fit™ app. The PrO2™ is a flow-resistive device that provides inspiratory resistance via a fixed 2mm orifice and has Bluetooth connectivity to most IOS/Android devices or Mac/Windows computers. The PrO2™ device and app allows for both 100% adherence monitoring and immediate user biofeedback. Participants will be instructed to inspire forcefully through PrO2™ until the device signals that the user has achieved the target resistance (via audible alarm and visible light signal). The research team will implement biofeedback signals at a specific inspiratory resistance to provide precise and individualized training target. Successful IMR repetitions will require that subjects achieve a pressure target that is 60% of their MIP.
• Pro2 - 15% of participant's MIP
Participants in the control intervention will also use the same PrO2™ device but at a reduced peak resistance of 15% MIP. The research team will implement biofeedback signals at a specific inspiratory resistance to provide precise and individualized training target. Successful IMR repetitions will require that subjects achieve a pressure target that is 15% of their MIP for each repetition

Locations

Country	Name	City	State
United States	Duke Healthy Lifestyles Clinic	Durham	North Carolina

Sponsors (2)

Lead Sponsor	Collaborator
Duke University	American Lung Association

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Demonstrate the safety of IMR	Participants are asked every week during the follow up calls if there are any adverse events	approximately 2 months
Primary	Adherence to active IMR Adherence to active IMR	Prevalence of IMR completion (actual / planned reps over intervention period) in active IMR group	approximately 2 months
Primary	Participant satisfaction among active IMR participants	Prevalence of agree or strongly agree to question of satisfaction with active IMR	approximately 2 months
Primary	Prevalence of completer status	Completion of study Visit 3	approximately 2 months
Secondary	Demonstrate changes in inspiratory muscle function with IMR.	Change in maximum inspiratory pressure (MIP) over intervention period	approximately 2 months
Secondary	Demonstrate changes in respiratory symptoms following IMR.	Participants are asked every week during the follow up calls if there are any health improvements	approximately 2 months